Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment

[1]  A. Feber,et al.  Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial. , 2022, JAMA.

[2]  E. Parlagreco,et al.  New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond , 2022, Cells.

[3]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). , 2021, European urology.

[4]  D. Bajorin,et al.  Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. , 2021, The Lancet. Oncology.

[5]  S. Shariat,et al.  Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis , 2021, Cancers.

[6]  J. Catto,et al.  Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes , 2021, European urology.

[7]  J. Catto,et al.  Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y. Lotan,et al.  Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists , 2020, Urologic Oncology: Seminars and Original Investigations.

[9]  I. Tsaur,et al.  Global change of surgical and oncological clinical practice in urology during early COVID-19 pandemic , 2020, World Journal of Urology.

[10]  Q. Le,et al.  Effect of Treatment Preference in Randomized Controlled Trials: Systematic Review of the Literature and Meta-Analysis , 2019, The Patient - Patient-Centered Outcomes Research.

[11]  F Reed Johnson,et al.  The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  M. Babjuk,et al.  What to do during Bacillus Calmette–Guérin shortage? Valid strategies based on evidence , 2018, Current opinion in urology.

[13]  D. Barocas,et al.  Quality of Life After Radical Cystectomy. , 2018, The Urologic clinics of North America.

[14]  M. Ryan,et al.  The Best of Both Worlds: An Example Mixed Methods Approach to Understand Men’s Preferences for the Treatment of Lower Urinary Tract Symptoms , 2018, The Patient - Patient-Centered Outcomes Research.

[15]  Ilene G. Ladd,et al.  Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer , 2018, Bladder cancer.

[16]  J. Catto,et al.  The patients’ experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence , 2017, Journal of Cancer Survivorship.

[17]  D. Lamm,et al.  Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Linda S Yang,et al.  A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. , 2016, Surgical oncology.

[19]  M. Abbod,et al.  The long‐term outcome of treated high‐risk nonmuscle‐invasive bladder cancer , 2012, Cancer.

[20]  David Parkin,et al.  Assessing the performance of the EQ-VAS in the NHS PROMs programme , 2012, Quality of Life Research.

[21]  M. P. Fransen,et al.  Applicability of Internationally Available Health Literacy Measures in the Netherlands , 2011, Journal of health communication.

[22]  J. Witjes,et al.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. , 2009, European urology.

[23]  Joanna Coast,et al.  Developing attributes and levels for discrete choice experiments using qualitative methods , 2007, Journal of health services research & policy.

[24]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[25]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Rimer,et al.  General Performance on a Numeracy Scale among Highly Educated Samples , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[28]  A. Zlotta,et al.  CUA GUIDELINE Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Full-text , 2021 .

[29]  Daniel J. Lee,et al.  The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer. , 2018, Cancer treatment and research.